UNSPSC 51352402: Chlordiazepoxide/estrogens

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS300. This VA Drug Class (HS300) classifies this compound as belonging to the group ESTROGENS.

UNSPSC 51352402 Chlordiazepoxide/estrogens is a Commodity code that captures state and local procurement of branded and generic pharmaceutical products, including hormone-replacement therapies and related pharmaceutical compounds, though recent solicitations show broader pharmacy benefit program activity extending well beyond this specific drug combination. State and local issuing bodies acquiring under this code include state health and human services departments, state cooperative purchasing alliances, and participating local government facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, and the Texas Health and Human Services Commission represent major recent buyers. Solicitations under the code seek manufacturers capable of supplying products through authorized wholesaler networks, maintaining current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, managing multiple pricing models (fixed, net price formats, WAC-minus), and delivering products with defined shelf-life and expiration requirements. Vendors must hold substantial insurance coverage (including $5,000,000 commercial general liability per occurrence) and demonstrate electronic data interchange (EDI) capability and flexibility in direct contracting arrangements outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent activity concentrates in the upper Midwest and Texas. The Minnesota Department of Administration's Office of State Procurement issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products covering participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026; pricing competitiveness carries 75 percent weight in evaluation. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013) in March 2026 to gather vendor capabilities and market intelligence on direct-to-manufacturer prescription programs outside existing PBM and GPO arrangements, with a response deadline of April 3, 2026. Neither solicitation discloses specific award values, set-aside designations, or budget ranges; both represent early-stage or intelligence-gathering phases in the state procurement cycle.